Entries by LRuas

Novo Holdings invests in water technology company Aquafortus

Aquafortus, a water technology company that purifies high salinity brines and derives valuable metals and minerals from them in the process, today announced the closing of a $17 million oversubscribed Series A1 financing led by DCVC and Novo Holdings, and joined by Universal Materials Incubator, Intrepid Financial Partners, Envisioning Partners, Burnt Island Ventures, K1W1 and […]

Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemics

Fourteen research projects will focus on antiviral research and drug development for henipaviruses, a subgroup of viruses with pandemic potential. Today, the partners in Pandemic Antiviral Discovery (PAD) initiative announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in […]

Prof. Molly Stevens receives the Novo Nordisk Prize – Understanding how materials and biology interact has revolutionised healthcare technologies

Science of small things does not sound like something that can have a big impact on the world, but nanotechnology has proved this is wrong. Tissue engineering, efficient drug delivery and more sensitive screening for diseases are just a few examples. According to Professor Molly Stevens, the new technologies can democratise access to healthcare. She […]

Changing the way we see CAR-T – Building out, not down

Co-founder and Chief Scientific Officer at Leucid Bio, Dr John Maher is revolutionising Chimeric Antigen Receptor (CAR) T-cell therapy, by designing CARs that are more powerful than predecessors and tough enough to tackle solid tumours. Dr Maher began his academic career at Trinity College, Dublin and has held numerous clinical, research and teaching positions at […]

Novo Holdings participates in Hemab Therapeutics $135M Series B Financing

Hemab Therapeutics is a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future […]